his puts us at 1.4 million square feet, 16% above our five-quarter leasing goal of 1.2 million square feet with six months still remaining. In addition, we continued to pursue our highly disciplined investment strategy in the second quarter, highlighted by our new Ardsley Park campus where we were able to add a very desirable property to our New York portfolio and concurrently sign a long-term lease with a top-tier tenant in Acorda Therapeutics, which we expect to result in a superior risk-adjusted rate of return. This high level of operating success continues to drive exceptional top-line and bottom-line results and provides further evidence of the power of building a business on the foundation of providing high-quality, well-located real estate to the life science industry."
Second Quarter 2011 Financial ResultsTotal revenues for the second quarter were $106.8 million, compared to $92.9 million for the same period in 2010, an increase of 14.9%, and the highest in the company's history for the third consecutive quarter. Rental revenues for the second quarter were $81.4 million, compared to $72.4 million for the same period in 2010, an increase of 12.5%, also the highest in the company's history for the third consecutive quarter.
The current operating portfolio's leased percentage increased to 90.5% as of June 30, 2011. Same property net operating income on a cash basis increased 6.8% for the quarter compared to the same period in 2010, primarily driven by sustained leasing success, commencement of cash rents, and contractual rent escalations.
Net income available to common stockholders for the second quarter was $3.6 million, or $0.03 per diluted share, compared to $4.2 million, or $0.04 per diluted share, for the same period in 2010. FFO for the quarter was $42.1 million, or $0.29 per diluted share, compared to $33.1 million, or $0.27 per diluted share, for the same period in 2010. AFFO for the quarter was
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1
|SOURCE BioMed Realty Trust, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Boston University Biomedical Engineers Find Chink in Bacterias Armor2
. Nobel Prize Awarded to Foundation for Biomedical Research Board Member3
. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU4
. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications5
. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards6
. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute7
. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications8
. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 20099
. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.10
. Voler Systems President Speaks at BIOMEDevice San Jose11
. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research